间充质干细胞来源外泌体作为药物载体递送微小RNA-29b通过激活自噬改善角膜损伤炎症
本研究以骨髓间充质干细胞来源外泌体负载miR-29b-3p治疗小鼠角膜损伤,发现负载miR-29b-3p的外泌体可激活自噬并抑制角膜炎症和纤维化,效果优于其他外泌体及PBS对照,并在人角膜上皮细胞中验证了miR-29b-3p过表达可预防自噬损伤和炎症损伤。
要点
- 负载miR-29b-3p的骨髓间充质干细胞外泌体(Exos-29b-ago)可改善小鼠角膜损伤的炎症和纤维化。
- Exos-29b-ago通过抑制PI3K/AKT/mTOR通路激活自噬,并经mTOR/NF-κB/IL-1β通路抑制炎症。
- Exos-29b-ago治疗后III型胶原、α-平滑肌肌动蛋白、纤连蛋白和波形蛋白表达较其他组显著降低。
核心结论
- 携带miR-29b-3p的骨髓间充质干细胞外泌体可通过激活自噬并进一步抑制角膜炎症和纤维化,显著提高角膜损伤的治疗效果。
研究设计与样本
- 研究将骨髓间充质干细胞转染miR-29b-3p agomir/antagomir及阴性对照获得Exos-29b-ago、Exos-29b-anta和Exos-NC,用于治疗接受角膜损伤手术的C57BL/6J小鼠,并设PBS组。
- 通过裂隙灯、苏木精-伊红染色、免疫荧光、RT-qPCR和Western blot评估角膜自噬、炎症和纤维化。
- 同时在永生化人角膜上皮细胞(iHCECs)中研究miR-29b-3p对自噬和炎症的影响。
主要发现
- 与PBS相比,Exos-29b-ago、Exos-29b-anta和Exos-NC均能改善角膜炎症和纤维化。
- Exos-29b-ago富集大量miR-29b-3p,通过抑制PI3K/AKT/mTOR通路激活自噬,并经mTOR/NF-κB/IL-1β通路抑制角膜炎症,效果优异。
- Exos-29b-ago治疗后III型胶原、α-平滑肌肌动蛋白、纤连蛋白和波形蛋白表达较其他组显著降低。
- 在iHCECs中,miR-29b-3p过表达可预防自噬损伤和炎症损伤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Corneal injury (CI) resulting in corneal opacity remains a clinical challenge. Exosomes (Exos) derived from bone marrow mesenchymal stem cells (BMSCs) have been proven effective in repairing various tissue injuries and are also considered excellent drug carriers due to their biological properties. Recently, microRNA-29b (miR-29b) was found to play an important role in the autophagy regulation which correlates with cell inflammation and fibrosis. However, the effects of miR-29b and autophagy on CI remain unclear. To find better treatments for CI, we used Exos to carry miR-29b and investigated its effects in the treatment of CI. METHODS: BMSCs were transfected with miR-29b-3p agomir/antagomir and negative controls (NCs) to obtain Exos-29b-ago, Exos-29b-anta, and Exos-NC. C57BL/6J mice that underwent CI surgeries were treated with Exos-29b-ago, Exos-29b-anta, Exos-NC, or PBS. The autophagy, inflammation, and fibrosis of the cornea were estimated by slit-lamp, hematoxylin and eosin (H&E) staining, immunofluorescence, RT‒qPCR, and Western blot. The effects of miR-29b-3p on autophagy and inflammation in immortalized human corneal epithelial cells (iHCECs) were also investigated. RESULTS: Compared to PBS, Exos-29b-ago, Exos-29b-anta, and Exos-NC all could ameliorate corneal inflammation and fibrosis. However, Exos-29b-ago, which accumulated a large amount of miR-29b-3p, exerted excellent potency via autophagy activation by inhibiting the PI3K/AKT/mTOR pathway and further inhibited corneal inflammation via the mTOR/NF-κB/IL-1β pathway. After Exos-29b-ago treatment, the expressions of collagen type III, α-smooth muscle actin, fibronectin, and vimentin were significantly decreased than in other groups. In addition, overexpression of miR-29b-3p prevented iHCECs from autophagy impairment and inflammatory injury. CONCLUSIONS: Exos from BMSCs carrying miR-29b-3p can significantly improve the therapeutic effect on CI via activating autophagy and further inhibiting corneal inflammation and fibrosis.
引用
- Liu J, Gao J, Lu P, et al. Mesenchymal Stem Cell-Derived Exosomes as Drug Carriers for Delivering miRNA-29b to Ameliorate Inflammation in Corneal Injury Via Activating Autophagy. Invest Ophthalmol Vis Sci. 2024. PMID: 38856990. doi:10.1167/iovs.65.6.16
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。